At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,289 enrolled
Drug / intervention
Ipilimumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 3 clinical trial evaluating Ipilimumab, Placebo, and 2 other interventions for Lung Cancer - Non Small Cell Squamous. Completed, enrolled 1,289 participants across 290 sites in 36 countries.
Detailed Summary
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer - Non Small Cell Squamous
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJun 2015
Study CompletionAug 2017
TodayJul 2026
First PostedJan 28, 2011
Enrollment StartJan 16, 2011
Primary CompletionJun 9, 2015
Study CompletionAug 22, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.4 years ago
Interventions
Ipilimumabdrug
Placebodrug
Paclitaxeldrug
Carboplatindrug